PIQRAY DIN 02497077
Health Canada record
| Active ingredient(s) | ALPELISIB 200 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EM03 ALPELISIB |
| Original market date | 29-Jun-2020 |
| Current status date | 29-Jun-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Novartis Pharmaceuticals Canada Inc — licence 100273, currently licensed, last inspection rating C (2025-01-14).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ALPELISIB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02497042 | PIQRAY | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | ALPELISIB 50 MG | Approved |
| 02497069 | PIQRAY | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet | ALPELISIB 150 MG | Marketed |
| 02497085 | PIQRAY | NOVARTIS PHARMACEUTICALS CANADA INC | Tablet; Kit | ALPELISIB 50 MG; ALPELISIB 200 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 23331 | 2020-03-11 | New Drug Submission (NDS) |
International API supply for ALPELISIB
1 active FDA Drug Master Files.
Request a quote for PIQRAY